Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
ALEVE-D SINUS & COLD is a fixed-dose combination oral tablet combining naproxen sodium (an NSAID) and pseudoephedrine hydrochloride (a decongestant) in extended-release formulation. It is indicated for temporary relief of sinus congestion, nasal congestion, and associated cold/flu symptoms including headache and body aches. The product addresses multi-symptom relief by combining anti-inflammatory and vasoconstrictive mechanisms.
As a mature OTC product approaching loss of exclusivity, the brand team is likely focused on defensive strategies and line extensions rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ALEVE-D in its LOE-approaching phase offers exposure to defensive brand strategy, generic competition management, and portfolio optimization—valuable skills for OTC and mature product roles. However, limited clinical development and declining career posting activity indicate this is not a growth-driver asset and may offer fewer advancement opportunities compared to emerging products.
Worked on ALEVE-D SINUS & COLD at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.